Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP

Neuropsychopharmacology

Volumn 33, Issue 11, 2008, Pages 2626-2634

  Sartorius, Leah J ^a,b   Weinberger, Daniel R ^a   Hyde, Thomas M ^a   Harrison, Paul J ^b   Kleinman, Joel E ^a   Lipska, Barbara K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bipolar disorder; Glutamate; Metabotropic; mGluR3; Neuroleptic; Post mortem

Indexed keywords

CLOZAPINE; HALOPERIDOL; MESSENGER RNA; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DRUG EFFECT; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HIPPOCAMPUS; HUMAN; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; RISK FACTOR; RNA EXTRACTION; RNA SPLICING; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANIMALS; EXONS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PREFRONTAL CORTEX; PROTEIN ISOFORMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RISK FACTORS; SCHIZOPHRENIA; UP-REGULATION;

EID: 45349086319     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301669     Document Type: Article

References (36)

1. Battaglia G, Bruno V, Ngomba RT, Di Grezia R, Copani A, Nicoletti F (1998). Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death. Eur J Pharmacol 356: 271-274.
2. Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003). ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31: 3568-3571.
3. Chen Q, He G, Chen Q, Wu S, Xu Y, Feng G et al (2005). A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 73: 21-26.
4. Comings DE, MacMurray JP (2000). Molecular heterosis: a review. Mol Genet Metab 71: 19-31.
5. Conn PJ, Pin JP (1997). Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205-237.
6. Corti C, Crepaldi L, Mion S, Roth AL, Xuereb JH, Ferraguti F et al (2007). Altered dimerization of metabotropic glutamate receptor 3 in schizophrenia. Biol Psychiatry 62: 747-755.
7. Crook JM, Akil M, Law BC, Hyde TM, Kleinman JE (2002). Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. Mol Psychiatry 7: 157-164.
8. de Quervain DJ, Papassotiropoulos A (2006). Identification of a genetic cluster influencing memory performance and hippocampal activity in humans. Proc Natl Acad Sci USA 103: 4270-4274.
9. East SJ, Hill MP, Brotchie JM (1995). Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. Eur J Pharmacol 277: 117-121.
10. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR (2004). Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 101: 12604-12609.
11. Fairbrother WG, Yeh RF, Sharp PA, Burge CB (2002). Predictive identification of exonic splicing enhancers in human genes. Science 297: 1007-1013.
12. Fallin MD, Lasseter VK, Avramopoulos D, Nicodemus KK, Wolyniec PS, McGrath JA et al (2005). Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 77: 918-936.
13. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N et al (2003). Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 13: 71-76.
14. Green E, Grozeva D, Norton N, Jones I, Jones L, O'Donovan MC et al (2006). Variation at GRM3 influences susceptibility to psychotic bipolar disorder [Abstract]. Am J Med Genet B Neuropsychiatr Genet 141B: 683-824.
15. Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, Meador-Woodruff JH (2005). Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57: 123-131.
16. Harrison PJ, Weinberger DR (2005). Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10: 40-68; image 5.
17. Javitt DC (2004). Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9: 984-997, 979.
18. Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179: 303-309.
19. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R et al (2006). Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 50 SNPs associated with the disease. Proc Natl Acad Sci USA 103: 6747-6752.
20. Lipska BK, Deep-Soboslay A, Shannon Weickert C, Hyde TM, Martin CE, Herman MM et al (2006a). Critical factors in gene expression in postmortem human brain: focus on studies in schizophrenia. Biol Psychiatry 60: 650-658.
21. Lipska BK, Peters T, Hyde TM, Halim N, Horowitz C, Mitkus S et al (2006b). Expression of DISC1 binding partners is reduced in schizophrenia and associated with DISC1 SNPs. Hum Mol Genet 15: 1245-1258.
22. Lovinger DM, McCool BA (1995). Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3. J Neurophysiol 73: 1076-1083.
23. Marti SB, Cichon S, Propping P, Nothen M (2002). Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 114: 46-50.
24. Moghaddam B, Adams BW (1998). Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.[comment]. Science 281: 1349-1352.
25. Norton N, Williams HJ, Dwyer S, Ivanov D, Preece AC, Gerrish A et al (2005). No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 5: 23.
26. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1998). Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 56: 207-217.
27. Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S et al (2004). NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J Neurochem 89: 876-885.
28. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107.
29. Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH (2000). Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 47: 22-28.
30. Sartorius LJ, Nagappan G, Lipska BK, Lu B, Sei Y, Ren-Patterson R et al (2006). Alternative splicing of human metabotropic glutamate receptor 3. J Neurochem 96: 1139-1148.
31. Schwab SG, Plummer C, Doyle A, Albus M, Borrman-Hassenbach M, Maier W et al (2006). Association with schizophrenia in three candidate genes: GRM-3, AKT-1 and NRG-1 [Abstract]. Am J Med Genet B Neuropsychiatr Genet 141B: 683-824.
32. Straub RE, Weinberger DR (2006). Schizophrenia genes - famine to feast. Biol Psychiatry 60: 81-83.
33. Tascedda F, Blom JM, Brunello N, Zolin K, Gennarelli M, Colzi A et al (2001). Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50: 117-122.
34. Tochigi M, Suga M, Ohashi J, Otowa T, Yamasue H, Kasai K et al (2006). No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population [Abstract]. Am J Med GenetB Neuropsychiatr Genet 141B: 683-824.
35. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
36. Yoshino M, Sawada S, Yamamoto C, Kamiya H (1996). A metabotropic glutamate receptor agonist DCG-IV suppresses synaptic transmission at mossy fiber pathway of the guinea pig hippocampus. Neurosci Lett 207: 70-72.